Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of “Buy” from Brokerages

Structure Therapeutics Inc. (NASDAQ:GPCR) has been given an average rating of “Buy” by the seven analysts that are covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $84.63.

A number of analysts have weighed in on GPCR shares. JPMorgan Chase & Co. started coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They issued an “overweight” rating and a $65.00 price target on the stock. JMP Securities lowered their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research report on Thursday. Finally, BMO Capital Markets increased their target price on Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, June 7th.

Hedge Funds Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its position in Structure Therapeutics by 404.0% in the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after purchasing an additional 3,504,747 shares during the period. Avoro Capital Advisors LLC grew its position in shares of Structure Therapeutics by 133.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after buying an additional 1,333,333 shares during the period. Federated Hermes Inc. raised its stake in shares of Structure Therapeutics by 104.2% during the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after buying an additional 1,157,006 shares during the last quarter. RA Capital Management L.P. raised its stake in shares of Structure Therapeutics by 210.2% during the first quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock worth $64,734,000 after buying an additional 1,023,530 shares during the last quarter. Finally, Capital International Investors acquired a new position in Structure Therapeutics in the fourth quarter valued at approximately $34,647,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 1.7 %

GPCR opened at $37.12 on Monday. The stock has a market cap of $1.73 billion, a PE ratio of -48.21 and a beta of -3.52. Structure Therapeutics has a 1 year low of $25.57 and a 1 year high of $75.02. The stock’s 50 day simple moving average is $40.24 and its 200-day simple moving average is $40.50.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Equities analysts forecast that Structure Therapeutics will post -0.94 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.